Form 57.124 Antimicrobial Use and Resistance (AUR): Pharmacy Data Mo

[NCEZID] The National Healthcare Safety Network (NHSN)

57.124 Antimicrobial Use and Resistance (AUR)-Pharmacy Data Electronic Upload Specification Tables-Clean Version

57.124 Antimicrobial Use and Resistence (AUR) - Pharmacy Data

OMB: 0920-0666

Document [docx]
Download: docx | pdf

Form Approved

OMB No. 0920-0666

Exp. Date: 06/30/26

www.cdc.gov/nhsn


Antimicrobial Use and Resistance (AUR): Pharmacy Data

Monthly Electronic Upload Specification Tables


These data will be collected in an aggregate monthly electronic file transfer from the facility to NHSN via Clinical Document Architecture (CDA).

Table 1. CDA File Descriptors

These data elements will be transmitted with each month’s report.

Variable Name

Description of Variable

Facility OID

NHSN Facility ID number

Application OID

Vendor software ID number

SDS validation ID

ID provided by NHSN Team confirming vendor software passed validation

location

NHSN location code

month

Denominator month

year

Denominator year

Table 2. Aggregate Patient Information

These data elements are aggregated to the location and facility wide inpatient level for each month.

Variable Name

Description of Variable

numDaysPresent

Total number of days present

numTherapyDays

Number of therapy days

numAdmissions

Number of admissions

Table 3. Aggregate Pharmacy Information

These data elements are obtained from the facility’s electronic medication administration record (eMAR) or bar coding medication administration (BCMA) and aggregated to the location and facility wide inpatient level for each month.

Variable Name

Description of Variable

Examples

drugIngredient

Antimicrobial ingredient

(see Table 3a)

routeDrugAdmin

Route of administration

Digestive tract, respiratory tract, intravenous route, intramuscular route

Table 3a. List of Antimicrobials Accepted

This is the list of antimicrobials currently accepted into NHSN as part of the antimicrobial use reporting.

Amantadine

Aztreonam

Cefoxitin

Clarithromycin

Fidaxomicin

Meropenem

Oseltamivir

Rifampin

Amikacin

Baloxavir marboxil

Cefpodoxime

Clindamycin

Fluconazole

Meropenem/ Vaborbactam

Oxacillin

Rimantadine

Amikacin Liposomal

Caspofungin

Cefprozil

Colistimethate

Fosfomycin

Metronidazole

Penicillin G

Sulfamethoxazole/ Trimethoprim

Amoxicillin

Cefaclor

Ceftaroline

Colistin

Gemifloxacin

Micafungin

Penicillin V

Tedizolid

Amoxicillin/ Clavulanate

Cefadroxil

Ceftazidime

Dalbavancin

Gentamicin

Minocycline

Peramivir

Telavancin

Amphotericin B

Cefazolin

Ceftazidime/ Avibactam

Daptomycin

Imipenem/ Cilastatin

Molnupiravir

Piperacillin/ Tazobactam

Tetracycline

Amphotericin B lipid complex

Cefdinir

Ceftolozane/ Tazobactam

Delafloxacin

Imipenem/ Cilastatin/ Relebactam

Moxifloxacin

Plazomicin

Tigecycline

Amphotericin B liposomal

Cefepime

Ceftriaxone

Dicloxacillin

Isavuconazonium

Nafcillin

Polymyxin B

Tinidazole

Ampicillin

Cefiderocol

Cefuroxime

Doxycycline

Itraconazole

Nirmatrelvir

Posaconazole

Tobramycin

Ampicillin/ Sulbactam

Cefixime

Cephalexin

Eravacycline

Lefamulin

Nitrofurantoin

Quinupristin/ Dalfopristin

Vancomycin

Anidulafungin

Cefotaxime

Chloramphenicol

Ertapenem

Levofloxacin

Omadacycline

Remdesivir

Voriconazole

Azithromycin

Cefotetan

Ciprofloxacin

Erythromycin

Linezolid

Oritavancin

Rezafungin

Zanamivir

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

Public reporting burden of this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333 ATTN: PRA (0920-0666).

CDC 57.124 v8, 12.0


Page 5 of 5

File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
File TitleAUR: Pharmacy Data Monthly Electronic Upload Specification Tables
SubjectNHSN AU Toolkit
AuthorCDC/NCEZID/DHQP
File Modified0000-00-00
File Created2023-11-20

© 2024 OMB.report | Privacy Policy